The Senate Already Voted on the Hemp Deadline. It Kept It, 61-32.

Affiliate disclosure: we earn a commission if you buy through links on this page, at no extra cost to you. Every price, quote and statutory citation below was read off the source we name, on the date we name.

The Short Verdict

On 8 August 2026, at 2:36 in the morning, the United States Senate took a recorded vote on an amendment whose entire stated purpose was five words long: "To strike section 2019." Section 2019 is the provision that narrowed the federal hemp ban and pushed most of it back to 11 December 2026. The Senate set that amendment aside by a vote of 61 to 32, and section 2019 survived into public law four weeks later.

We have read the roll call page itself. This is the single most load-bearing fact in the hemp calendar right now, and we have not seen it cited by its vote number in the trade coverage we read. It is Record Vote 227 of the second session of the 119th Congress.

What it means in practice: the 11 December date is not an accident of drafting, and it is not a rumour started by brands running countdown banners. A named senator moved to delete it, the Senate voted on that motion by name, and the motion lost. That is the strongest available evidence that the December carve-in was deliberate. It is not, however, evidence that 11 December is the date every product on the shelf loses hemp status, and the second half of this article is about the difference. Our running record of every date, bill and regulator statement is in the federal hemp THC deadline tracker, and the brands merchandising the deadline on their own storefronts are covered in our December 11 brand warning. Soul is the only brand we cover that prints the calendar date in words on its own product page.

What the roll call actually says

Transcribed from the Senate's own roll call vote page for Record Vote 227, second session, 119th Congress.

The "Statement of Purpose" field is the part worth dwelling on. Senate roll call pages carry a one-line description of what an amendment was meant to do, written for the record rather than for the press. It is a field almost nobody reads, and on this vote it removes all ambiguity about what the chamber was deciding. The amendment was not a technical correction and it was not about a different subject that happened to touch hemp. Its purpose, as stated on the official page, was to delete section 2019.

Twenty-one Republicans were among the 32 senators who voted against tabling. We are giving the count only and not a roster, because a roster is the kind of detail that is easy to transcribe wrongly and we have not verified it name by name.

Why a motion to table is not the same as a vote on the merits

This distinction matters, and getting it wrong is how a good fact turns into a bad headline.

A motion to table is a procedural motion to set something aside. When the Senate agrees to table an amendment, the amendment is dead, but the chamber has not taken a direct up-or-down vote on whether it agreed with the amendment's substance. Senators vote to table for all sorts of reasons, including timing, a deal on the underlying bill, or an unwillingness to reopen a negotiated text at half past two in the morning.

So the precise reading is this: 61 senators voted to set aside an amendment that would have struck section 2019, and 32 voted to keep that amendment alive. The effect was to leave section 2019 in the bill. The correct inference is that the Senate declined to remove the provision when it was asked to, by name, on the record. The incorrect inference, which we are not making, is that 61 senators affirmatively endorsed the hemp delay on its merits.

Even on the narrower reading, it is decisive for our purposes. A provision that survives a named motion to strike, on a recorded vote, in the middle of a marathon amendment session, is a provision the chamber knew was there.

What section 2019 does, and what section 781 did

Two different acts, passed ten months apart, carry confusingly similar names. Tell them apart by section number, never by year.

Section 2019's operative sentence, read off the enrolled text, is short enough to quote in full:

"Until December 11, 2026, the amendments made by section 781 of division B of Public Law 119-37 (7 U.S.C. 1639o note) shall only apply with respect to products described in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) of section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o) (as amended by such section 781)."

Its heading reads "SEC. 2019. SECTION 781 EXTENSION." Notice what it is not: it is not a change to the effective date of section 781. Section 781 still takes effect 365 days after 12 November 2025, which is 12 November 2026. What section 2019 does is restrict which subclauses of the new definition apply in the interim. We read those two subclauses as the ones covering cannabinoids that a cannabis plant cannot naturally produce, which leaves the cannabinoids that a plant can produce but that were made outside it, and the quantitative limits, waiting until 11 December. We walk through that subclause structure in full in which cannabinoids lose hemp status.

One open construction question we flag rather than resolve: whether "Until December 11, 2026" includes the 11th. We read it as lapsing on that day, and we say so as a reading rather than as settled law.

Three independent records of the same vote

We do not publish a load-bearing fact off one document. This one has three.

• The Senate's roll call page for Record Vote 227 carries every field in the table above, including the Statement of Purpose.
• The legislative status record for H.R. 6500 states: "Motion to table amendment SA 6747 agreed to in Senate by Yea-Nay Vote. 61 - 32. Record Vote Number: 227." That is where we confirmed Budd as the sponsor.
• Congressional Research Service report R49353, at footnote 11, describes the same event: "Under the terms of a unanimous consent agreement, the Senate considered an amendment (S.Amdt. 6747) to Division B of the act that would have removed a provision delaying the implementation of a change in the statutory definition of hemp... The Senate agreed to table the amendment by a vote of 61-32."

The CRS footnote is useful for a second reason: it is a neutral government description of what the amendment would have done, and it calls section 2019 "a provision delaying the implementation of a change in the statutory definition of hemp." That is CRS's characterisation, not ours.

For completeness, the rest of the sequence: the Senate passed H.R. 6500 by 90 to 6 on 8 August as Record Vote 228, the House passed it 370 to 48 on 1 September as Record Vote 286, and the President signed it on 2 September 2026. It is Public Law 119-103, at 140 Stat. 987. Two research passes have offered us wrong signing dates for this law. It is 2 September.

What changed this week: S. 5526 reached the calendar without a written report

The Senate farm bill, which had been an unnumbered draft in our records for weeks, now has a number. We covered its arrival in what S. 5526 means for hemp. Reading the bill's legislative status record today added one detail we had not seen, and it is a useful one.

The status record lists exactly three actions, all dated 24 September 2026:

• "Placed on Senate Legislative Calendar under General Orders. Calendar No. 683."
• "Committee on Agriculture, Nutrition, and Forestry. Original measure reported to Senate by Senator Boozman. Without written report." The record carries this entry twice, identically. We quote it as found rather than reconciling it.

"Without written report" is the new fact. A farm bill of this size, twelve titles and a text file of roughly 1.4 megabytes, was reported to the Senate with no accompanying committee report. There is therefore no report language on hemp, because there is no report at all. That is a verified negative about the report, and it is a different thing from a verified negative about the bill text, which we still do not have.

Also from the status record, as of its 26 September timestamp: no cosponsors, no legislative subject terms assigned, no policy area, and no summaries. The Congressional Research Service has not yet processed the bill. Two portions of it carry their own short titles, the "Enhanced Cybersecurity for SNAP Act of 2026" and the "Watershed Protection and Flood Prevention Act."

We want to be exact about the limit of our own knowledge here. S. 5526's Title X is the horticulture title, which is where the 2018 farm bill put hemp. Every attempt we have made to read that title has failed, either because the file truncates partway through or because the route was unavailable, and today's attempt failed too. Reports elsewhere have described the Senate farm bill as having no hemp language in it. Every such statement we have read describes either the 23 June discussion draft or the pre-markup proposal, both of which predate the text that reached the calendar on 24 September. We are not asserting the opposite either. We are saying the question is open, and that we have not been able to close it.

The Senate's own calendar says it leaves on 5 October

This is the other thing we read today, and it reframes the next ten weeks.

The Senate publishes a Tentative 2026 Legislative Schedule. Its entries for the rest of the year, transcribed exactly as printed:

"State Work Period" is the Senate's term for the stretches when the chamber is not in Washington and senators are in their states. Three things follow, and we are stating them at exactly the confidence the document supports.

First, the schedule prints no State Work Period between 21 September and 5 October. The week in which the current farm bill extension expires is, on this schedule, a working week. That is now the third independent Senate-side primary agreeing on the point, and it is why we corrected a claim on our own tracker page yesterday: we had been carrying a trade outlet's forecast that the Senate would leave for roughly six weeks before the elections, and the Senate's own documents do not support it. It had a departure date wrong, not the departure.

Second, the schedule does give us the departure date the forecast was reaching for: 5 October, eight days from today, running through 6 November, which spans the 3 November elections.

Third, and most consequentially for anyone selling or buying hemp products: 11 December falls inside no State Work Period on this schedule. The December period begins on the 21st, ten days later. On its own published calendar, the Senate is scheduled to be in Washington on the day the hemp carve-in lapses and the day government funding runs out. Whether it does anything with that day is a separate question we are not going to predict.

Two limits on all of the above, both from the document itself. The page is titled "Tentative." And it prints no legend, so what a blank middle column means, as on the 11 to 13 November row, is not stated anywhere on the page. We are not going to tell you what that row means. We are telling you what it says.

The three days that matter first

Day counts are our own arithmetic from today, Sunday 27 September 2026.

The overlap on 11 December is not a coincidence anyone designed for hemp's benefit. It means the hemp deadline arrives inside a government funding negotiation, which is the same vehicle that produced section 781 in the first place and then section 2019 to soften it.

What this vote does not settle

Here is the part that most coverage skips.

The 61-32 vote tells you section 2019 is deliberate. It does not tell you which products fall on which side of which date, because that turns on the subclause structure of section 781, and on three lists the Food and Drug Administration was required to publish and has not.

Our standing sentence on the FDA, which we print unchanged wherever this comes up: FDA has issued no 2026 Federal Register rulemaking directed at cannabinoids. Its only 2026 Federal Register discussion of delta-8 THC appears as a supporting example in the preamble to a proposed rule about something else, the 11 August 2026 GRAS proposed rule, Docket FDA-2025-N-3262, and FDA's own cannabis page is still marked content-current as of July 2024. The lists were due 10 February 2026. By our count they are 229 days late as of today.

The practical consequence is that the restrictions take effect regardless; the missing lists determine only how far past total THC the exclusions reach.

On the date that matters commercially, the one for cannabinoids made from CBD, the professional reading is genuinely split. Our reading traces the subclause numbers and lands on 11 December. That is a minority reading among the law firms we have read. Several firms, including Bradley Arant in the strongest opposing analysis we have seen, put converted delta-8 and its relatives on 12 November. One law firm has stated expressly that the November acceleration is limited to the "not capable of being naturally produced" category, which is the structural half of our argument, without ever naming delta-8.

So here is our advice, unchanged: plan for 12 November and treat 11 December as upside. We never state as flat fact that the December date is the one governing CBD-converted delta-8. And there is an operational reason to plan for November regardless of what the federal answer turns out to be: Illinois repeals its Industrial Hemp Act on 12 November, New Jersey's own dates land on 13 and 14 November, and Virginia's SB 543 threshold arrives on 1 November. Those bite through state law whatever the federal reading. State by state, that is all in our hemp and THC legality guide by state.

There is also a separate legal regime that this vote does not touch at all. The Agricultural Marketing Act definition decides whether something is hemp. The Controlled Substances Act decides whether something is scheduled. The DEA's position, stated in a rule published on 4 May 2026, is that tetrahydrocannabinols produced through chemical conversion are synthetically produced for CSA purposes even when hemp derived. Never merge the two regimes; a product can clear one and not the other.

What it means for what is on the shelf

The number almost nobody explains properly is the per-container limit. Our standing wording: 0.4 mg combined total per container, covering total THC plus other cannabinoids the FDA is required to list as having similar effects, a list the FDA has never published.

"Container" is statutory, and the definition is broad: the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product. A gummy jar is a container. So is a cream jar, which is why this limit reaches topicals and not only edibles, a point we make on our CBD creams and topicals ranking.

Jonathan Miller, general counsel of the U.S. Hemp Roundtable, put the scale of it in one sentence: "Even the vast majority of non-intoxicating CBD products have more than 0.4 milligrams of THC per container."

Here is that claim checked against products we have actually priced. Printed figures come off the brand's own product page on the date given. The per-container totals and the multiples are our arithmetic.

The Soul row is the one that explains the rule best. A 1.5 mg gummy is a microdose, the lowest per-gummy THC figure in our verified price set, and a jar of thirty still carries 112.5 times the coming per-container limit. This is not a high-dose rule. It is a rule that a compliant jar of hemp gummies essentially cannot satisfy while containing meaningful THC at all.

Two of those rows are worth noticing side by side for a different reason. Five's Daily Buzz and Medterra's Daily Delight are spec-identical, 5 mg THC and 25 mg CBD in a 20-count, and priced identically at $39.99. If you are choosing between them, it is not going to be on price. Our full lane-by-lane comparison is in best delta-9 gummies 2026.

If your interest is CBD rather than THC, the cheapest gummy per milligram in our set is CBDfx's Original Mixed Berry at roughly 3.7 cents per mg of CBD, with one disclosure attached: CBDfx does not print the jar count on that page, so the 60-count figure the arithmetic rests on is ours, not theirs. Rankings for that category are in best CBD gummies 2026, and the oils are in best CBD oil 2026.

Our Three Picks

These are the three brands we would send a reader to today, given a vote that makes the December carve-in look deliberate and a calendar that puts the Senate in town when it lapses. Full scoring methodology is on our how we review page, and all twelve brands are compared side by side in best CBD and hemp brands 2026.

• Medterra - MCR Score 8.8/10. Our highest-scored brand, and the most transparent pricing structure of the set: every subscription figure is exactly 0.75 times the list price, with no sitewide sale to decode. It is also one of three brands we cover that printed no deadline language of any kind when we checked its storefront on 23 September, which we read as a brand that has not updated its legal boilerplate rather than one making a claim. Read the Medterra review.
• Soul - MCR Score 8.6/10. The only brand we cover that prints the calendar date in words on a product page: "Ships until December 11, 2026," read on 25 September. Whatever you think of the merchandising, it is the most honest disclosure of a shipping cut-off any of our partners has published. One caveat, which the page discloses itself: its multi-month tiers read as prepaid bulk supplies rather than deliveries scheduled into 2027, and we have not tested the fulfilment, so read the terms. Read the Soul review.
• CBDfx - MCR Score 8.4/10. The best lab documentation of any brand we carry: per-strength, per-batch certificates with batch numbers and dates, and an archive running from 2020 to the present. Its struck-through prices are genuine one-time sale prices rather than subscription figures, which is not true of every brand in this category. Note the shipping threshold conflict on its own site; we use the $99 figure.

Lab Testing

A vote in the Senate does not change what is in the jar, and the per-container limit above is going to be measured against a certificate of analysis, not a marketing claim. If you read one thing on this site that is not about dates, make it our guide to reading a COA. It covers total THC versus delta-9 THC, which is precisely the distinction section 781 turns on, and batch matching, which is how you tell a real certificate from a decorative one.

Where our partners stand, as of our most recent checks: CBDfx publishes its lab reports per strength and per batch with dates, and claims ISO 17025 accreditation, though the most recent certificate we found for one of its calming products was dated September 2025. Medterra offers QR batch lookup and states ISO 17025, and discloses openly that it does not test for herbicides or glyphosate, which we would rather have stated than hidden. Vena has the weakest lab disclosure of any brand we carry: its certificates are a shared cloud folder with no batch lookup, no named laboratory and no dates. We say that on the four big listicles and in our brands coverage, and we are saying it here.

Buy if, look elsewhere

Buy now if: you use a specific hemp THC product regularly and would be genuinely inconvenienced by it disappearing. The 61-32 vote is good evidence the December carve-in was intentional, but the carve-in is a narrowing with an expiry date, not a reprieve, and the professional split on which products move in November is real. Koi and Vena both still had full catalogues when we last checked, on 25 September.

Look elsewhere, or wait, if: you are buying on the strength of a countdown timer. Those timers are dynamic, we have watched one decrement across calendar days, and a banner is not a statute. Also look elsewhere if a brand's own site tells you both things at once. Four of the six partner brands we checked in late September still print a 2018 farm bill legality claim, and three of them print it on the same page as their own December warning. We read that as un-updated boilerplate rather than deception, but it is a reason to get your legal dates from a primary source rather than a footer.

Do not buy on the assumption that: a tabled amendment means Congress has settled this. The same chamber that declined to strike section 2019 in August has a farm bill on its calendar that we cannot fully read, a funding deadline on the same day as the hemp deadline, and a scheduled absence running from 5 October to 6 November that begins eight days from now.

Frequently asked questions

Did the Senate vote to ban hemp? No. The 8 August vote was on a motion to set aside an amendment that would have struck section 2019, which is the provision that narrows the hemp restrictions until 11 December 2026. The motion to table succeeded 61 to 32, so section 2019 stayed in the bill.

What is Record Vote 227? It is the Senate's numbering for that roll call: vote 227 of the second session of the 119th Congress, taken at 2:36 a.m. on 8 August 2026 on the motion to table Budd Amendment No. 6747.

Who sponsored the amendment? Sen. Ted Budd of North Carolina, confirmed from the legislative status record for H.R. 6500.

Does this mean 11 December is the deadline for delta-8? That is our reading, traced through the subclause numbers of section 781, and it is a minority reading among the law firms we have read. Several put converted cannabinoids on 12 November instead. Plan for 12 November and treat 11 December as upside.

Is the Senate in session when the hemp deadline hits? On its own Tentative 2026 Legislative Schedule, 11 December falls inside no State Work Period, and the December period begins on the 21st. The schedule is labelled tentative and we are quoting it, not predicting from it.

Could Congress delay the deadline again? It has done it once, through section 2019, and there are bills pending that would go further, including H.R. 9830, which we analysed in our Lawful Hemp Protection Act breakdown. None has had a markup or a hearing. We are not forecasting.

What is the 0.4 mg limit exactly? 0.4 mg combined total per container, covering total THC plus other cannabinoids the FDA is required to list as having similar effects, a list the FDA has never published. "Container" is statutory and means the innermost wrapping in direct contact with the product, so a cream jar counts.

Sources

• United States Senate, roll call votes of the 119th Congress, 2nd session, Record Vote 227, "On the Motion to Table (Motion to Table Budd Amdt. No. 6747)."
• Legislative status record for H.R. 6500, 119th Congress, via GovInfo bulk data.
• Congressional Research Service, Report R49353, footnote 11.
• Legislative status record for S. 5526, 119th Congress, via GovInfo bulk data, read 27 September 2026.
• United States Senate, "Tentative 2026 Legislative Schedule," read 27 September 2026.
• United States Senate floor schedule, read 27 September 2026.
• Public Law 119-103, enrolled text, section 2019 and section 106 of Division A.
• Public Law 119-37, division B, section 781.
• Drug Enforcement Administration final rule of 4 May 2026, 91 Fed. Reg. No. 85.
• Food and Drug Administration proposed rule of 11 August 2026, Docket FDA-2025-N-3262.
• Jonathan Miller, U.S. Hemp Roundtable, quoted by Harvest Public Media, 17 September 2026.
• Brand product pages for Soul, Five, Medterra, Vena and CBDfx, read on the dates given in the tables above.

Affiliate disclosure: we earn a commission if you buy through links on this page, at no extra cost to you. Nothing on this page is legal advice. We are a review site reading primary sources, not a law firm, and the reading of section 2019 and section 781 set out above is ours. If a compliance decision turns on these dates, get a lawyer.